Pretreatment of Uterine Fibroids Using a Selective Progesterone Receptor Modulator - Ulipristal Acetate

We report on the findings of a prospective clinical audit of the use of Ulipristal acetate for pre-treatment of symptomatic uterine fibroids in a multi-ethnic population. A total of 59 women given a 3-months treatment course of Ulipristal Acetate 5mg daily were studied. Primary outcome measures were fibroid volume reduction and amenorrhoea rates. Analysis showed that although fibroid volume reduction rates were comparable to those published in the PEARL I and II studies, amenorrhoea rates were significantly lower. Our study population has a significantly higher representation of black women which may suggest that racial differences influence selective progesterone receptor modulator treatment responses.